VCYT

Veracyte, Inc.

$24.01

-1.32%
Nov 16, 2026
Bobby Quantitative Model
Veracyte, Inc. is a genomic diagnostics company that develops and commercializes molecular tests designed to help clinicians diagnose and treat cancer at pivotal decision points, with a portfolio spanning thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), and bladder cancer (Decipher Bladder), operating within the healthcare diagnostics and research industry. The company occupies a specialized niche as a commercial-stage genomic testing platform, monetizing primarily through its Testing segment (roughly 97% of revenue) rather than through biopharma partnerships or product sales, which gives it a recurring, volume-driven revenue model tied to clinical adoption and reimbursement. The current investor narrative is dominated by a violent post-earnings repricing: despite reporting Q3 2026 revenue of $151.8 million (up 15.1% year over year) and net income of $31.5 million, the stock collapsed roughly 54% in a single session on November 5, 2026, suggesting guidance, reimbursement dynamics, or competitive concerns (including Natera's expanding bladder cancer franchise) overshadowed the headline beat. The debate now centers on whether this is a temporary sentiment shock in an otherwise profitable, cash-generative franchise or the beginning of a structural deceleration in test volume growth and pricing.

People also watch

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

TMO

Analysis
Danaher Corporation

Danaher Corporation

DHR

Analysis
Natera

Natera

NTRA

Analysis
IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

IDXX

Analysis
Agilent Technologies

Agilent Technologies

A

Analysis

BobbyInvestment Opinion: Should I buy VCYT Today?

Rating: Hold (with a speculative accumulation bias for risk-tolerant investors). The core thesis is that Veracyte's reported fundamentals — 15.08% YoY revenue growth to $151.75 million, a 20.76% net margin, $161.41 million of trailing free cash flow, and a debt-to-equity of just 0.030 — are fundamentally incompatible with a stock that fell 54% in a single session to $24.33, but the market's violent repricing on the November 5 earnings date signals information (guidance, reimbursement, or Natera competition) that reported numbers do not yet capture. Five of six analysts (Stephens, Freedom Capital, Piper Sandler, UBS, Needham) reiterated Buy/Overweight ratings post-crash with a tight EPS consensus of $2.175 (range $2.118-$2.260), implying targets sit well above the current price, but no explicit average target is available to quantify the upside.

The supporting evidence for not selling here is substantial: at $24.33 against $2.175 consensus EPS, the stock trades at roughly 11.2x forward earnings, a PEG of 0.31, and a PS of 6.40x versus a historical PS band of roughly 14.3x (Q2 2024) to 43.5x (Q4 2021). Gross margin has held in a stable 69%-74% band (70.58% in Q3 2026), operating margin reached 10.92%, and the company has now delivered four consecutive profitable quarters after the Q2 2025 loss, while the current ratio of 8.15 and $201.47 million of cash (even after a $153.19 million acquisition outflow) remove financing risk entirely. The counterweight is that EV/EBITDA of 33.31x and price-to-cash-flow of 24.27x remain premium multiples that leave little cushion if estimates are cut, and the trailing PE of 50.12x versus ~11x forward implies the market expects earnings to roughly quadruple.

The biggest risks that could invalidate the thesis are (1) the November 5 disclosure proving to be the leading edge of structural deceleration — reimbursement cuts on a core test or Natera Signatera share gains in bladder cancer driving Q4 growth below 10%; (2) analyst estimates proving stale, with the $2.175 EPS consensus cut and the ~11x forward multiple revealed as illusory because the denominator falls; and (3) a technical breakdown below the $23.16 52-week low opening a fresh leg lower with no visible floor. This Hold would upgrade to Buy if Q4 results confirm revenue growth holds above 15% with stable reimbursement and the stock reclaims the $26-$27 post-gap consolidation zone, and would downgrade to Sell on a decisive break below $23 or evidence of reimbursement compression in the Testing segment. On valuation, the stock is deeply undervalued relative to its own history and growth profile but only fairly-to-richly valued on EBITDA and cash flow — the verdict hinges entirely on whether reported growth is durable.

Sign up to view all

VCYT 12-Month Price Forecast

The forward view is genuinely two-sided: reported fundamentals (15.08% growth, 20.76% net margin, $161.41 million FCF, negligible 0.030 debt-to-equity) argue the ~11.2x forward multiple is a deep discount, while the -54% single-session gap and -60.32% max drawdown argue the market has priced in deterioration that analyst estimates have not yet reflected. The tight 6.7% EPS estimate spread and five reiterated Buy ratings suggest high conviction in near-term earnings, but the Leerink downgrade to Market Perform on the earnings date is the one signal that at least one analyst sees competitive or reimbursement pressure the others have not priced. The base case (50% probability, $28-$36) assumes growth decelerates modestly but stays double-digit and the stock bases above $23.16, while the 25% bull case ($45-$52) requires Q4 confirmation of 15%+ growth and the 25% bear case ($16-$23) follows a break below the 52-week low on estimate cuts. I would upgrade to bullish on a Q4 print showing revenue growth above 15% with stable reimbursement and a reclaim of $26-$27, and downgrade to bearish on a decisive break below $23 or evidence of reimbursement compression in the Testing segment.

Historical Price
Current Price $24.01
Average Target $24.01
High Target $27.61
Low Target $20.41

Wall Street consensus

Six analysts cover Veracyte, and the institutional ratings flow is overwhelmingly constructive despite the price collapse: Stephens & Co. (Overweight), Freedom Capital Markets (Buy), Piper Sandler (Overweight), UBS (Buy), and Needham (Buy) all reiterated bullish ratings in the days following the November 5 crash, with only Leerink Partners downgrading from Outperform to Market Perform on the earnings date itself. The consensus leans clearly bullish, and the estimated EPS average of $2.175 (range $2.118-$2.260) and revenue average of $928.61 million (range $909.87-$956.55 million) imply analysts have not yet slashed estimates to match the stock's collapse. Notably, no explicit average price target is provided in the data, so implied upside cannot be calculated directly; however, the persistence of Buy ratings after a 54% single-day decline strongly implies targets sit well above the current $24.33. The target range and signal strength must be inferred from the estimate dispersion and rating actions. The tight EPS range ($2.118-$2.260, a spread of only ~6.7%) signals high conviction in near-term earnings, while the revenue range ($909.87-$956.55 million, a ~5.1% spread) is similarly narrow, suggesting analysts broadly agree on the fundamental trajectory even as the stock price diverges wildly from it. The high end of estimates assumes sustained 15%+ testing growth and stable reimbursement, while the low end prices in modest deceleration; the Leerink downgrade to Market Perform is the one cautionary signal, hinting at concern over competitive pressure (notably Natera's bladder cancer expansion) or reimbursement risk. The wide gap between analyst conviction and market pricing is the central tension — either the selloff is an overreaction that creates significant upside to consensus targets, or analysts are lagging a fundamental deterioration the market has already recognized.

Drowning in data?

Find the real signal!

Bulls vs Bears: VCYT Investment Factors

The bear case currently has stronger near-term evidence: a -54% single-session gap, a -60.32% max drawdown, and a stock pinned 4.9% above its 52-week low all indicate the market has repriced the growth story on information (likely guidance, reimbursement, or Natera competition) that outweighs the reported 15.1% revenue growth and 20.76% net margin. The bull case rests on a genuine disconnect — ~11x forward earnings, 0.31 PEG, $161.41 million trailing FCF, and five of six analysts reiterating Buy — but analyst estimates may simply lag a deterioration the market has already recognized. The single most important tension is whether the November 5 disclosure signals a temporary sentiment shock or the start of structural deceleration in test volume and pricing; if Q4 results confirm growth holds above 15% with stable reimbursement, the valuation gap closes violently upward, but if guidance implied a slowdown, the stock has further to fall toward and below $23.16. Until the next earnings print resolves this, the evidence favors caution over conviction on either side.

Bullish

  • Forward PE near 11x is deeply discounted: At $24.33 against consensus forward EPS of $2.175, VCYT trades at roughly 11.2x forward earnings — a remarkably low multiple for a franchise growing revenue 15.1% YoY with a 70.6% gross margin. The PEG ratio of 0.31 and PS of 6.40x sit far below the stock's own historical PS band of roughly 14.3x (Q2 2024) to 43.5x (Q4 2021), implying the market has already priced in severe deterioration.
  • Profitability inflected sharply upward: Q3 2026 net income of $31.50 million produced a 20.76% net margin, up from $19.14 million and a 14.51% margin in Q3 2025, marking four consecutive profitable quarters after the Q2 2025 loss. Gross margin held at 70.58% and operating margin reached 10.92%, showing operating leverage is materializing even as the share price collapsed.
  • Fortress balance sheet, self-funding model: Debt-to-equity is just 0.030 and the current ratio is 8.15, with $201.47 million of cash even after a $153.19 million acquisition outflow in Q3. Trailing free cash flow of $161.41 million against only $2.33 million of quarterly capex means the company funds itself entirely from operations, removing financing risk from the thesis.
  • Analyst conviction intact post-crash: Five of six covering analysts (Stephens, Freedom Capital, Piper Sandler, UBS, Needham) reiterated Buy/Overweight ratings in the days after the November 5 collapse, with only Leerink downgrading to Market Perform. The tight EPS estimate range of $2.118-$2.260 (a ~6.7% spread) signals high conviction that near-term earnings are not deteriorating, creating a wide gap versus market pricing.

Bearish

  • Catastrophic 54% single-day earnings gap: The stock gapped from $52.52 on November 4 to $24.00 on November 5 and has failed to reclaim even $26 in six subsequent sessions, closing at $24.33. A gap of that magnitude on an earnings date typically reflects guidance cuts, reimbursement concerns, or competitive disclosures that the headline revenue beat does not capture — the market is voting that something structural changed.
  • Severe downtrend with no technical floor: VCYT sits just 4.9% above its 52-week low of ~$23.16 and 59.8% below its June 2026 high of ~$60.49, with a max drawdown of -60.32%. A decisive break below $23 would open a fresh leg lower with no visible support, and the -44.08% one-month change shows the damage is accelerating rather than stabilizing.
  • Natera competitive threat in bladder cancer: Natera's Signatera won Japan PMDA approval as a bladder cancer CDx in September 2026, its second approval in three months, directly pressuring Veracyte's Decipher Bladder franchise. With Testing at $146.42 million of $151.75 million total revenue (~96.5%), any share loss in a core test line hits the entire revenue base disproportionately.
  • Extreme single-product concentration: The Testing segment contributes ~96.5% of revenue while Product ($4.63 million) and Biopharma/Other ($0.71 million) are immaterial, so the investment case rests entirely on clinical test volume and reimbursement per test. There is no diversification buffer if reimbursement pressure or competitive share loss materializes in any single franchise.

VCYT Technical Analysis

Veracyte is in a severe, confirmed downtrend that has erased more than a year of gains. The stock is down 38.98% over the past year and 42.60% year-to-date, and at $24.33 it sits just 4.9% above its 52-week low of roughly $23.16 and roughly 59.8% below its 52-week high of approximately $60.49 (set in late June 2026). Trading at the very bottom of its 52-week range after a -60.32% maximum drawdown signals capitulation-style selling rather than a healthy pullback, and the positioning implies the market has fully repriced the growth story rather than merely trimming an overextended multiple. Momentum has deteriorated catastrophically in the short term. The 1-month change of -44.08% and 3-month change of -41.02% are both dramatically worse than the 1-year decline of -38.98%, meaning the bulk of the damage occurred in the last quarter and accelerated sharply in November. The single-session gap from $52.52 on November 4 to $24.00 on November 5 is a textbook earnings-driven breakdown, and the failure to reclaim even $26 in the subsequent six sessions (closing at $24.33 on November 13) indicates no meaningful dip-buying support. Relative strength versus the S&P 500 is deeply negative across every window (-41.82% over 1 month, -51.25% over 1 year, -53.22% YTD), confirming this is idiosyncratic company-specific selling rather than sector-wide weakness. Key levels are now starkly defined. Immediate support sits at the 52-week low near $23.16, and a decisive break below that level would open the door to a fresh leg lower with no visible technical floor, while resistance is stacked at the post-gap consolidation zone around $26-$27 and then the pre-earnings shelf near $50. A reclaim of $26-$27 would be the first sign of stabilization, whereas a breakdown below $23 would confirm the downtrend's continuation. With a beta unavailable in the provided data, volatility must be inferred from the realized price action itself, and the -60.32% max drawdown and 54% single-day gap imply realized volatility far in excess of the broad market, warranting materially smaller position sizing and wider stops for anyone attempting to catch this falling knife.

Beta

—

—

Max Drawdown

-60.3%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

-39.0%

Cumulative gain past year

PeriodVCYT ReturnS&P 500
1m-44.3%-3.0%
3m-41.0%-3.6%
6m-46.9%-0.2%
1y-39.0%+10.1%
ytd-43.4%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

VCYT Fundamental Analysis

The revenue trajectory remains solidly positive even as the stock price collapses, creating a sharp disconnect between operating performance and market sentiment. Q3 2026 revenue of $151.75 million grew 15.08% year over year versus $131.87 million in Q3 2025, and the sequential progression from $139.07 million in Q1 to $150.32 million in Q2 to $151.75 million in Q3 shows steady, if modestly decelerating, sequential expansion. The Testing segment dominates the mix at $146.42 million, dwarfing Product at $4.63 million and Biopharmaceutical/Other at just $0.71 million, meaning the entire investment case hinges on clinical test volume and reimbursement per test rather than diversification. Full-year 2026 consensus revenue of approximately $928.6 million against a trailing base implies continued double-digit growth, so the November selloff appears driven by forward guidance or competitive/reimbursement fears rather than any deterioration in reported top-line results. Profitability has improved markedly and is no longer the issue. Q3 2026 net income reached $31.50 million for a 20.76% net margin, up from $19.14 million (14.51% margin) in Q3 2025, while gross margin held at a strong 70.58% and operating margin came in at 10.92%. The gross margin trend has been remarkably stable in the 69%-74% band across the last several quarters (72.21% in Q2 2026, 72.32% in Q1 2026, 74.43% in Q4 2025), consistent with the high-margin economics typical of molecular diagnostics once tests are reimbursed at scale, and the company has now strung together four consecutive profitable quarters after a loss in Q2 2025. The balance sheet is fortress-like and cash generation is robust. Debt-to-equity is a negligible 0.030, the current ratio stands at an exceptional 8.15, and cash at the end of Q3 2026 was $201.47 million even after a $153.19 million acquisition outflow during the quarter. Trailing free cash flow is $161.41 million, quarterly operating cash flow was $40.26 million against just $2.33 million of capex, and ROE is 5.07% — modest but positive and improving. The company is fully self-funding, carries essentially no leverage risk, and the Q3 cash decline reflects deliberate M&A investment rather than operational burn, which makes the equity selloff look increasingly disconnected from balance-sheet reality.

Quarterly Revenue

$151754000.0B

2026-09

Revenue YoY Growth

+15.1%

YoY Comparison

Gross Margin

70.6%

Latest Quarter

Free Cash Flow

$161414000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Biopharmaceutical And Other
Product
Testing

Open an Account, get $2 TSLA now!

Valuation Analysis: Is VCYT Overvalued?

Because Veracyte is profitable (Q3 2026 net income of $31.50 million; trailing EPS of $0.0201 per the key metrics feed, though quarterly diluted EPS of $0.38 annualizes to a far higher run-rate), the PE ratio is the appropriate primary metric, and the trailing PE of 50.12x versus a forward PE of just 0.31x is a data artifact rather than a genuine signal — the forward figure appears to be a mislabeled PEG or EPS-derived ratio and should be treated with caution. Using the more reliable forward EPS consensus of $2.175 against the $24.33 price, the stock trades at roughly 11.2x forward earnings, which is remarkably cheap for a 15%-growth, 70%-gross-margin diagnostics franchise and suggests the market is pricing in severe estimate cuts or a growth stall. On peer comparison, the PS ratio of 6.40x and EV/EBITDA of 33.31x sit at a premium to mature diagnostics names but well below the historical genomics-testing cohort, while the PEG ratio of 0.31 and PB of 2.53x imply the market has already de-rated the stock aggressively relative to its growth and asset base. The spread between the 50.12x trailing PE and the ~11x forward PE implies the market expects earnings to roughly quadruple, which is plausible given the quarterly EPS run-rate of $0.38-$0.52 versus the trailing figure, but the disconnect also flags how violently the multiple has compressed. Historically, Veracyte's PS ratio has ranged from roughly 14.3x (Q2 2024) to 43.5x (Q4 2021), and the current 6.40x is far below even the low end of that band, while the PE history shows swings from negative territory in 2023 to 141x in Q4 2024 and 50x today. The stock is trading near the bottom of its own historical valuation range on virtually every metric, which either represents a compelling value opportunity if the growth story is intact or reflects the market's judgment that fundamental deterioration (reimbursement pressure, competitive share loss) is underway — the November gap suggests investors currently believe the latter.

PE

50.1x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 20x~141x

vs. Industry Avg

35.2x

Industry PE ~35.2x*

EV/EBITDA

33.3x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on concentration and the durability of the recent margin inflection. Testing accounts for ~96.5% of the $151.75 million quarterly revenue, so the entire P&L hinges on clinical test volume and reimbursement per test with no diversification buffer. The four-quarter profitability streak (Q3 2026 net margin 20.76%, up from 14.51% a year earlier) is young and could reverse quickly if reimbursement per test compresses, and the $153.19 million Q3 acquisition outflow — which cut cash to $201.47 million — adds integration and impairment risk. ROE of just 5.07% and trailing EPS of $0.0201 show that despite strong gross margins (70.58%), bottom-line economics remain thin relative to the asset base, leaving earnings highly sensitive to any volume or pricing shock.

Market and competitive risks are elevated by the stock's own volatility and an intensifying rival. The -60.32% max drawdown and 54% single-day gap imply realized volatility far in excess of the broad market, and relative strength versus the S&P 500 is deeply negative across every window (-41.82% over one month, -51.25% over one year), confirming idiosyncratic selling rather than sector rotation. Natera's Signatera Japan PMDA bladder cancer CDx approval in September 2026 directly threatens Decipher Bladder, and the Leerink downgrade to Market Perform on the earnings date hints that at least one analyst sees competitive or reimbursement pressure the others have not yet priced. Even after the collapse, EV/EBITDA of 33.31x and P/CF of 24.27x leave valuation compression risk if estimates are cut.

Worst-case scenario: the November 5 disclosure proves to be the leading edge of a structural slowdown — reimbursement cuts on a core test plus Natera share gains in bladder cancer drive Q4 revenue growth below 10%, analysts slash the $2.175 EPS consensus, and the ~11x forward multiple proves illusory because the denominator falls. In that chain, the stock breaks the $23.16 52-week low with no technical floor, and the realistic downside from $24.33 is roughly -25% to -35% (to the $16-$18 range) before value buyers re-engage, with a tail scenario matching the -60.32% historical max drawdown if guidance is cut outright. An investor buying today could lose 25-35% from current levels in this adverse path.

FAQ

Ranked by severity: first, company-specific execution risk — Testing is ~96.5% of the $151.75 million quarterly revenue, so any reimbursement cut or volume loss in a single franchise hits the whole P&L, and the four-quarter profitability streak (20.76% net margin in Q3 2026) is young enough to reverse. Second, competitive risk — Natera's Signatera won Japan PMDA approval as a bladder cancer CDx in September 2026, directly pressuring Decipher Bladder, and Leerink's downgrade to Market Perform on the earnings date hints at concerns the other five analysts have not priced. Third, valuation/estimate risk — EV/EBITDA of 33.31x and P/CF of 24.27x mean the ~11.2x forward multiple is illusory if the $2.175 EPS consensus is cut, since the denominator would fall alongside the price. Fourth, technical and momentum risk — the stock is 4.9% above its $23.16 52-week low after a -60.32% max drawdown, and a decisive break below $23 would open a fresh leg lower with no visible support.

The scenario framework is 50% base case, 25% bull case, and 25% bear case. The base case targets $28-$36 and assumes Q4 2026 revenue growth decelerates to the 10%-15% range without turning negative, reimbursement per test holds stable, the $2.175 EPS consensus survives with only modest revisions, and the stock bases above $23.16 and reclaims the $26-$27 consolidation zone. The bull case targets $45-$52 and requires Q4 confirmation of 15%+ growth with stable reimbursement plus management clarifying that the November 5 disclosure was conservative or one-time, allowing the ~11.2x multiple to re-rate toward historical levels. The bear case targets $16-$23 and follows growth below 10% on reimbursement cuts or Natera share gains, a material cut to the $2.175 EPS consensus, and a break below the 52-week low with no technical floor. The base case is most likely, and its key assumption is that reported fundamentals did not collapse — but the wide $16-$52 span reflects genuine two-sided uncertainty.

The answer depends on the metric, which is precisely the tension. On forward earnings the stock looks deeply undervalued: ~11.2x on $2.175 consensus EPS, a PEG of 0.31, a PS of 6.40x versus a historical band of roughly 14.3x (Q2 2024) to 43.5x (Q4 2021), and a PB of 2.53x all sit near the bottom of the stock's own history. On cash-flow and EBITDA metrics it is still premium: EV/EBITDA of 33.31x and price-to-cash-flow of 24.27x leave little cushion, and the trailing PE of 50.12x versus the ~11x forward figure implies the market expects earnings to roughly quadruple. The market is therefore pricing in either a sharp earnings step-up or meaningful estimate cuts — the November gap suggests investors currently lean toward the latter. Verdict: undervalued relative to its growth profile and history, but only fairly-to-richly valued on EBITDA and cash flow, so the discount is conditional on reported growth proving durable.

On a risk/reward basis VCYT screens as asymmetric but unproven: at $24.33 against $2.175 consensus EPS it trades at roughly 11.2x forward earnings with a 0.31 PEG, while five of six analysts (Stephens, Freedom Capital, Piper Sandler, UBS, Needham) reiterated Buy/Overweight after the crash, implying targets sit well above the current price even though no explicit average target is disclosed. The fundamental backdrop is genuinely strong — 15.08% YoY revenue growth, a 20.76% net margin, $161.41 million trailing free cash flow, and a 0.030 debt-to-equity — which is hard to reconcile with a -54% single-day decline. The offsetting risk is severe: the stock is 4.9% above its $23.16 52-week low, and a break below that level implies roughly -25% to -35% downside toward $16-$18 if estimates are cut. It is a reasonable buy only for risk-tolerant investors who size positions small and accept that the November 5 disclosure may reflect information the reported numbers do not yet capture; conservative investors should wait for Q4 confirmation of 15%+ growth and a reclaim of $26-$27.

VCYT is better suited to a long-term holding period of at least 12-24 months than to short-term trading. The company is a commercial-stage, self-funding diagnostics platform with 15.08% revenue growth, a 20.76% net margin, $161.41 million trailing free cash flow, and negligible leverage (debt-to-equity 0.030), which supports a multi-year thesis if reimbursement and test volumes hold. Short-term trading is hazardous: the stock gapped 54% in one session, has a -60.32% max drawdown, and sits 4.9% above its 52-week low with relative strength versus the S&P 500 at -41.82% over one month, so near-term direction is dominated by event risk rather than trend. There is no dividend (payout ratio 0) and no income support, and earnings visibility is clouded until the Q4 print resolves the guidance question. A reasonable minimum holding period is 12 months, ideally entered in tranches after either a reclaim of $26-$27 or a confirmed Q4 print showing 15%+ growth.